WOAG
WITHDRAWAL OF ATTORNEY GRANTED
03/27/2025
Back to search
Official data from USPTO
FIRST WAVE BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
03/28/2025
Trademark type
Combined
Nice classes
42
Filing date
11/11/2021
Registration date
08/22/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/22/2023
Last transaction
03/28/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2021-09-00
First use in commerce
2021-09-00
Drawing code
3
Owner type
03
Owner location
Boca Raton, FL
Examiner
SNYDER, NELSON
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "First Wave BioPharma" appearing above and to the right of a stylized cresting wave formed from three crescent-shaped designs. The largest crescent has a tail that extends below the mark wording, while a smaller crescent design appears to the immediate right of the largest crescent design. The smallest crescent-shaped design is positioned beneath the tail of the largest crescent.
Holders and representatives
Holders
FIRST WAVE BIOPHARMA, INC.
Representatives
FIRST WAVE BIOPHARMA, INC.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Biological research and analysis; Industrial research in the field of gastroenterologygastrohepatologyinflammatory diseasesinfectious diseasespharmaceuticals for the treatment thereof; Pharmaceutical drug development services; Pharmaceutical research and development; Research and development in the field of pharmaceuticals and pharmaceutical therapies for the treatment of gastrointestinal (GI) diseasesinflammatory diseasesinflammatory bowel diseases (IBD)ulcerative colitisulcerative proctitisCrohn's diseaseimmune checkpoint inhibitor-associated colitis (ICI-AC)exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitisinfectious diseasesCOVID-19 gastrointestinal infections; Research in the field of biopharmaceuticals; Scientific research and development
Publications
History of USPTO decisions and trademark events.
30 publications found
WOAR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
03/27/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/25/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/25/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/25/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/25/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/25/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/22/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/22/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/15/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/14/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/06/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/03/2023
IUAF
USE AMENDMENT FILED
06/06/2023
EISU
TEAS STATEMENT OF USE RECEIVED
06/06/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/06/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/11/2022
PUBO
PUBLISHED FOR OPPOSITION
10/11/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/21/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/08/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/07/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/07/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/07/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/01/2022
GNRT
NON-FINAL ACTION E-MAILED
09/01/2022
CNRT
NON-FINAL ACTION WRITTEN
09/01/2022
DOCK
ASSIGNED TO EXAMINER
08/23/2022
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
11/19/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/18/2021
NWAP
NEW APPLICATION ENTERED
11/15/2021
Continuous trademark protection
Get notified about every new filing that threatens FIRST WAVE BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.